Fulton Breakefield Broenniman LLC Gilead Sciences, Inc. Transaction History

Fulton Breakefield Broenniman LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 25, 2019	SELL	$61.87 - $69.38 $5.38 Million - $6.04 Million	-87,024 Closed	0 $0
Q1 2019 Apr 17, 2019	BUY	$62.53 - $70.05 $239,427 - $268,221	3,829 Added 4.6%	87,024 $5.66 Million
Q4 2018 Feb 05, 2019	SELL	$60.54 - $79.0 $129,737 - $169,297	-2,143 Reduced 2.51%	83,195 $5.2 Million
Q3 2018 Oct 24, 2018	SELL	$71.28 - $78.92 $19,744 - $21,860	-277 Reduced 0.32%	85,338 $6.59 Million
Q2 2018 Aug 02, 2018	BUY	$64.88 - $75.68 $200,608 - $234,002	3,092 Added 3.75%	85,615 $6.07 Million
Q1 2018 Apr 19, 2018	BUY	$72.84 - $88.8 $47,054 - $57,364	646 Added 0.79%	82,523 $6.22 Million
Q4 2017 Jan 30, 2018	BUY	$71.15 - $83.52 $153,826 - $180,570	2,162 Added 2.71%	81,877 $5.87 Million
Q3 2017 Oct 13, 2017	BUY	$72.11 - $85.47 $5.75 Million - $6.81 Million	79,715	79,715 $6.46 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Fulton Breakefield Broenniman LLC, based on Form 13F filings with the SEC.

Stay updated on Fulton Breakefield Broenniman LLC with notifications on news.